Zobrazeno 1 - 10
of 204
pro vyhledávání: '"Michael F Egan"'
Autor:
Lucas Kempf, Kristin K Nicodemus, Bhaskar Kolachana, Radhakrishna Vakkalanka, Beth A Verchinski, Michael F Egan, Richard E Straub, Venkata A Mattay, Joseph H Callicott, Daniel R Weinberger, Andreas Meyer-Lindenberg
Publikováno v:
PLoS Genetics, Vol 4, Iss 11, p e1000252 (2008)
PRODH, encoding proline oxidase (POX), has been associated with schizophrenia through linkage, association, and the 22q11 deletion syndrome (Velo-Cardio-Facial syndrome). Here, we show in a family-based sample that functional polymorphisms in PRODH a
Externí odkaz:
https://doaj.org/article/f5a0dd74f24b40efab11dfae81443706
Autor:
Tiffini Voss, James Kost, Swati Pal Mercer, Christine Furtek, Christopher Randolph, Christopher Lines, Michael F. Egan, Jeffrey L. Cummings
Publikováno v:
Journal of Alzheimer's Disease. 92:341-348
Background: Delay of progression from prodromal Alzheimer’s disease (AD) to dementia is an important outcome in AD trials. Centralized adjudication is intended to improve the consistency of dementia diagnosis but has not been scrutinized. Objective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7ce9428f0db21e600e8044fadb63835
https://doi.org/10.3233/jad-220836
https://doi.org/10.3233/jad-220836
Autor:
Cyrille Sur, Katarzyna Adamczuk, David Scott, James Kost, Mehul Sampat, Christopher Buckley, Gill Farrar, Ben Newton, Joyce Suhy, Idriss Bennacef, Michael F. Egan
Publikováno v:
Molecular Imaging and Biology. 24:862-873
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d3fe8c03e7e673ae78e9a53cea03daf
https://doi.org/10.1007/s11307-022-01735-z
https://doi.org/10.1007/s11307-022-01735-z
Autor:
Marissa F, Dockendorf, David, Jaworowicz, Rebecca, Humphrey, Melanie, Anderson, Sheila, Breidinger, Lei, Ma, Theresa, Taylor, Nicole, Dupre, Christopher, Jones, Christine, Furtek, Bhavna, Kantesaria, Kevin P, Bateman, Eric, Woolf, Michael F, Egan, Julie A, Stone
Publikováno v:
The AAPS Journal. 24
In-clinic venous dried blood spot (DBS) pharmacokinetic (PK) sampling was incorporated into two phase 3 studies of verubecestat for Alzheimer's disease (EPOCH [NCT01739348] and APECS [NCT01953601]), as a potential alternative to plasma PK sampling. I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6725a0a9e0d19ed66541455c65d683fb
https://doi.org/10.1208/s12248-022-00682-5
https://doi.org/10.1208/s12248-022-00682-5
Autor:
Cyrille, Sur, Katarzyna, Adamczuk, David, Scott, James, Kost, Mehul, Sampat, Christopher, Buckley, Gill, Farrar, Ben, Newton, Joyce, Suhy, Idriss, Bennacef, Michael F, Egan
Publikováno v:
Molecular imaging and biology. 24(6)
The BACE inhibitor verubecestat was previously found to reduce amyloid load as assessed byThe analyses addressed (1) identification of an optimalThe optimal subcortical white matter and pons SUVr cutoffs were determined to be 0.69 and 0.62, respectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fb4d6002f57528c4375fa4550981f293
https://pubmed.ncbi.nlm.nih.gov/35794343
https://pubmed.ncbi.nlm.nih.gov/35794343
Autor:
Daven Bigelow, Maureen E. Hupfer, Michael F. Egan, Calvin Hillis, Simon Ma, Brian Detlor, Rehan Theiveehathasan, David Harris Smith
Publikováno v:
EDULEARN Proceedings.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aaa11fbc28958f7d3bff9afcf7834516
https://doi.org/10.21125/edulearn.2021.0545
https://doi.org/10.21125/edulearn.2021.0545
Autor:
Michael F. Egan, Saheeda Jackson, Cyrille Sur, Robert C. Sergott, James Kost, Christine Furtek, Annaswamy Raji, Amy Locco, Britta A. Mattson, Arpankumar Patel
Publikováno v:
Journal of Alzheimer's disease : JAD. 79(1)
Background: We performed exploratory analyses of retinal thickness data from a clinical trial of the AβPP cleaving enzyme (BACE) inhibitor verubecestat in patients with Alzheimer’s disease (AD). Objective: To evaluate: 1) possible retinal thicknes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddc9bf12a74e0f0c4b00e601d976d4aa
https://pubmed.ncbi.nlm.nih.gov/33252075
https://pubmed.ncbi.nlm.nih.gov/33252075
Autor:
David Michelson, Robert S. Stern, Christopher Randolph, Paul S. Aisen, Craig Shering, Nicole Dupre, Alette M. Wessels, Christopher Lines, James Kost, Bruno Vellas, Lyn Harper Mozley, Pierre N. Tariot, Tiffini Voss, Michael F. Egan, Christine Furtek, Yuki Mukai, John R. Sims, Jeffrey L. Cummings, Scott W. Andersen
Publikováno v:
Alzheimer'sdementia : the journal of the Alzheimer's AssociationREFERENCES. 16(11)
Introduction The APECS and AMARANTH trials showed that beta-secretase (BACE) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early Alzheimer's disease. Here, the performance on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e7c442b70d759befbd7fc0eb9aa0342
https://pubmed.ncbi.nlm.nih.gov/33049114
https://pubmed.ncbi.nlm.nih.gov/33049114
Autor:
David Michelson, Martin R. Farlow, Jeffrey L Cummings, Linda Snow-Adami, Jerry Li, Christopher Assaid, Kerry Budd McMahon, Tiffini Voss, Michael F. Egan, Heather Leibensperger, Samar Froman
Publikováno v:
Alzheimer's & Dementia : Translational Research & Clinical Interventions
Introduction We evaluated the selective M1 muscarinic positive allosteric modulator, MK-7622, as adjunctive cognitive enhancing therapy in individuals with Alzheimer's disease. Methods A randomized, double-blind, proof-of-concept trial was performed.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b459a6a8ebc3ccd20c9802b9253f8648
https://doi.org/10.1016/j.trci.2018.03.004
https://doi.org/10.1016/j.trci.2018.03.004
Autor:
Pierre N. Tariot, James Kost, Bruno Vellas, Cyrille Sur, Matthew E. Kennedy, Tiffini Voss, Michael F. Egan, Christopher Lines, David Scott, Katarzyna Adamczuk, Yuki Mukai, Erin Mahoney, David Michelson, Jeffrey L. Cummings, Paul S. Aisen, Nick C. Fox
Publikováno v:
Brain
In the phase 3 EPOCH trial (Clinicaltrials.gov; NCT01739348), treatment with the BACE inhibitor verubecestat failed to improve cognition in patients with mild-to-moderate Alzheimer’s disease, but was associated with reduced hippocampal volume after
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4a010b8e9d3bbe845dbeb7f1beaaaf4
https://pubmed.ncbi.nlm.nih.gov/33253354
https://pubmed.ncbi.nlm.nih.gov/33253354